PR Newswire Clinical TrialsOriginal article
Blue Earth Therapeutics announces first participant dosed in Phase 1 clinical trial investigating Actinium (²²⁵Ac) rhPSMA-10.1 Injection in metastatic castration-resistant prostate cancer
Phase 1Actinium (²²⁵Ac) rhPSMA-10.1 InjectionPositive
AI Analysis
Summary
Blue Earth Therapeutics announces first participant enrollment in a Phase 1 clinical trial investigating Actinium-225 rhPSMA-10.1 for metastatic castration-resistant prostate cancer, evaluating safety, tolerability, and radiation dosimetry of the alpha-emitting radiopharmaceutical.
Clinical Trial Data
Phase
Phase 1
Outcome Details
First participant dosed in Phase 1 clinical trial
Importance:5/10
Sentiment:
0.60
Phase 1radiopharmaceuticalprostate canceralpha-emitterPSMA-targeted therapyclinical trial initiation
Read the original article
Published by PR Newswire Clinical Trials on July 9, 2026 5:01 AM